Healthcare, Pharma & Life Sciences

Hong Kong – November 06, 2026 -- Akeso's PD-1/VEGF bispecific antibody ivonescimab combined with chemotherapy produced a 70.1% major pathological response (MPR) rate and a 50.7% pathological complete response (pCR) rate in resectable non-small cell lung cancer (NSCLC), according to Phase II results published in Nature Medicine.

Chemotherapy combination delivers 70.1% MPR and 100% R0 resection

The trial tested perioperative ivonescimab as monotherapy or with chemotherapy. Patients received neoadjuvant treatment, then surgery, then adjuvant ivonescimab. Among patients who underwent surgery in the combination cohort, 68.7% had residual viable tumor of 5% or less.

NEW BRUNSWICK, N.J. – November 06, 2026 -- The U.S. Food and Drug Administration has granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), backed by a confirmed 42 percent overall response rate in a 102-patient cohort.

Approval covers post-platinum, post-immunotherapy patients and excludes HPV-associated oropharyngeal disease

The subcutaneous single-agent therapy is cleared for adults whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The indication excludes patients with HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). J&J says it is the first dual-targeted therapy approved in this setting, hitting both EGFR and MET, and describes it as the first advance in second-line treatment of the disease in a decade.

Shanghai – November 06, 2026 -- China's Center for Drug Evaluation (CDE) accepted Lynk Pharmaceuticals' New Drug Application for zemprocitinib in moderate-to-severe active rheumatoid arthritis (RA) on November 4, moving the oral JAK1 inhibitor into regulatory review.

430-patient Phase III trial beat placebo at p<0.0001

The filing rests on a randomized, double-blind, placebo-controlled, multicenter Phase III trial in China. It enrolled 430 adults with moderate-to-severe active RA who had an inadequate response or intolerance to prior biologic disease-modifying antirheumatic drugs (bDMARDs). Zemprocitinib showed statistically significant efficacy over placebo on the primary and key secondary endpoints (p<0.0001). Lynk reports an overall favorable safety and tolerability profile.

Berlin – November 05, 2026 -- The Federal Ministry of Health's own cost estimate projects a net deficit of €1.35 billion in 2027 for Germany's social long-term care insurance (SPV), even after the Care Reorganisation Act (PNOG) takes effect. Dr. Carola Reimann, chair of the AOK Federal Association, made the point as the Bundestag held the bill's first reading, and she called the law a stopgap that buys the SPV "a few months" of financial relief at most.

AOK demands a second law once the care commission reports in January

Reimann wants the open financing questions settled in a separate legislative procedure, a "PNOG 2". It would follow the recommendations of the Care Structure Commission (Pflegestrukturkommission), due at the end of January.

LEXINGTON, Mass. – November 05, 2026 -- Curis, Inc. (NASDAQ: CRIS) will report third-quarter 2026 financial and operating results on Thursday, November 12, 2026, at 4:00 p.m. ET, with a conference call and webcast following at 4:30 p.m. ET.

Curis ties acute myeloid leukemia expansion to new funding

The company's monotherapy and combination studies of emavusertib in acute myeloid leukemia (AML) are substantially complete. Curis plans to continue AML development only with additional funding, which makes the November 12 update a checkpoint on its financial position.

Spring Hill – November 05, 2026 -- Tampa General Hospital (TGH) and Lifepoint Rehabilitation plan to build a 40-bed inpatient rehabilitation hospital in Spring Hill, Florida, with an opening targeted for the second half of 2028.

The freestanding facility is planned near the TGH Spring Hill campus, pending customary regulatory approvals. It will treat patients recovering from stroke, brain and spinal cord injuries, neurological disorders, trauma, amputation and other complex medical conditions in Hernando County and surrounding communities.

Second Tampa-area inpatient rehabilitation partnership for TGH and Lifepoint

The project is the second inpatient rehabilitation hospital partnership between the two organizations in the greater Tampa market. It extends TGH's footprint in the region, where TGH North already comprises three hospitals and several outpatient locations in Citrus and Hernando counties.

SALT LAKE CITY – November 05, 2026 -- Co-Diagnostics, Inc. (Nasdaq: CODX) will release its third quarter 2026 financial results on Tuesday, November 10, after the market close, two days ahead of the previously announced date of Thursday, November 12.

Co-Diagnostics schedules a 4:30 p.m. ET call on the new date

The molecular diagnostics company will host a conference call and webcast at 4:30 p.m. ET on November 10 to discuss the results. Investors can join the webcast through the Events & Webcasts page of the company's investor relations site or dial in by toll-free or toll number. A recording will be posted on the company's website for those who cannot attend live.

Berlin – November 05, 2026 -- Germany's Care Restructuring Act (PNOG) will take effect on January 1 even if lawmakers amend it, and outpatient care providers are already cutting staff because parts of their services will no longer be funded from that date, according to a commentary in nd.DieWoche.

Federal loan repayment is deferred to 2035 under the PNOG

The draft law postpones repayment of federal loans used to plug care insurance funding gaps until 2035. The commentary argues the deferral resolves none of the underlying care-provision problems and that the bill creates new ones. The CDU has responded that the draft will be improved during the parliamentary process.

New York – November 05, 2026 -- The Vaccine Guidance Review Panel, a multi-society effort of four U.S. medical organizations, has endorsed influenza, RSV and COVID-19 vaccination recommendations for adults and children. The guidance is aligned with Advisory Committee on Immunization Practices (ACIP) recommendations issued before June 2025.

Panel draws on four specialty societies and four guidance issuers

Experts from the American Academy of Allergy, Asthma & Immunology (AAAAI), the American Thoracic Society (ATS), the American College of Chest Physicians (CHEST) and the Society of Critical Care Medicine (SCCM) reviewed the vaccination-development process. They unanimously endorsed it, together with the resulting guidance from the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG) and the Infectious Diseases Society of America (IDSA).

PLYMOUTH MEETING, Pa. – November 05, 2026 -- INOVIO Pharmaceuticals (Nasdaq: INO) plans to raise capital through an underwritten public offering of its common stock, with all shares sold by the company itself.

Underwriters hold a 30-day option on up to 15% additional shares

INOVIO intends to grant the underwriters a 30-day option to buy additional shares, capped at 15% of the shares sold in the base offering and priced on the same terms. The company has not disclosed the number of shares or the pricing. It said there is no assurance the offering will be completed, or on what size or terms, and that it remains subject to market conditions.

Jefferies and Piper Sandler are acting as joint book-running managers.